Loading organizations...
§ Private Profile · Wuhan, China
Investment firm providing capital and managing investments, focused on long-term value creation across diverse sectors and markets.
Changjiang Capital is a state-backed investment firm and asset management organization based in Wuhan, China, that focuses on industrial development, private equity, and venture capital. Operating as the primary investment vehicle for the Hubei provincial government, the firm strategically allocates capital across advanced manufacturing, healthcare, digital technology, and new energy sectors to stimulate regional economic growth. The organization currently manages an estimated $55 billion in total assets under management, deploying its capital through both direct equity investments and a broad network of affiliated industry funds. Throughout its operational history, the firm has built a substantial technology and automotive portfolio, backing prominent enterprises such as Yangtze Memory Technologies (YMTC), Lotus, Geely, and BOE Technology. Changjiang Capital was officially established in 2022 following the strategic consolidation of multiple regional state-owned investment platforms by the Hubei State-owned Assets Supervision and Administration Commission.
Changjiang Capital is involved in the co-management of the Hubei Changjiang Industrial Fund, which is identified as a buyout fund.
Changjiang Capital participates in a range of investment activities, including private equity, venture rounds, and mergers and acquisitions.
Changjiang Capital is headquartered in Wuhan, China.
Changjiang Capital is involved in the co-management of the Hubei Changjiang Industrial Fund, which is identified as a buyout fund.
Changjiang Capital participates in a range of investment activities, including private equity, venture rounds, and mergers and acquisitions.
Changjiang Capital is headquartered in Wuhan, China.
Changjiang Capital has 1 tracked investment across 1 company. The latest tracked deal is $14.4M Series C in Huaguan Biotechnology in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 4, 2026 | Huaguan Biotechnology | $14.4M Series C | — | Changzhou Qihang Synthetic Biology Venture Capital Fund, SDIC Venture Capital, Shunxi Fund, Zhuhai Hengqin Softbank Xinchuang Equity Investment Management Enterprise |